CD40 inhib 
Welcome,         Profile    Billing    Logout  
 11 Companies  12 Products   12 Products   40 Diseases   6 Trials   375 News 
14 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
daleuton oral (DS107 oral) / DS Biopharma
2017-004098-15: A Randomised, Double-blind, Placebo-controlled, Phase 2 Study to Assessthe Efficacy and Safety of Orally Administered DS107 in a once daily doseof 2g in Haemodialysis Patients with Moderate to Severe Uremic Pruritus

Ongoing
2
110
Europe
Dihomo-Gamma-Linolenic Acid, DGLA, DS107G, Capsule, soft
DS Biopharma, DS Biopharma
Moderate to Severe Uremic Pruritus, Moderate to Severe Uremic Pruritus, Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
2019-000932-25: Study to Assess the Efficacy and Safety of Orally Administered DS107 in Adult Patients with Moderate to Severe Atopic Dermatitis

Not yet recruiting
2
220
Europe
DS107 Capsule, DS107G, Capsule, soft
DS Biopharma Ltd., DS Biopharma Ltd.
Moderate to Severe Atopic Dermatitis, Moderate to Severe Atopic Dermatitis, Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
iscalimab (CFZ533) / Novartis
TWINSS, NCT03905525 / 2018-004476-35: Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome

Completed
2
273
Europe, Canada, Japan, US, RoW
CFZ533, iscalimab, Placebo
Novartis Pharmaceuticals
Sjögren Syndrome
09/22
06/23
CONTRAIL I, NCT03781414 / 2018-001836-24: Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension

Terminated
2
128
Europe, US, RoW
CFZ533, Tacrolimus - MMF - corticosteroids
Novartis Pharmaceuticals
Liver Transplant Rejection
04/23
04/23
NCT03610516 / 2017-003230-93: Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Lupus Nephritis.

Hourglass Jan 2021 - Dec 2021 : Data from trial for lupus nephritis
Completed
2
57
Europe, RoW
CFZ533, Placebo
Novartis Pharmaceuticals
Lupus Nephritis
06/23
06/23
TWINSS Extn, NCT04541589 / 2020-001942-20: Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome

Completed
2
206
Europe, Canada, Japan, US, RoW
CFZ533 (iscalimab), iscalimab, CFZ533 Placebo, Placebo
Novartis Pharmaceuticals
Sjogren's Syndrome
08/24
08/24
NCT03656562 / 2018-001508-12: Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients

Hourglass Sep 2021 - Dec 2021 : From trial for SLE
Active, not recruiting
2
107
Europe, Japan, RoW
VAY736, Ianalumab, VAY736 Placebo, Ianalumab/Placebo, CFZ533, Iscalimab, CFZ533 Placebo, Iscalimab/Placebo
Novartis Pharmaceuticals
Systemic Lupus Erythematosus (SLE)
07/22
04/26
CCFZ533X2207, NCT04129528 / 2018-004553-25: Study of Safety and Efficacy of CFZ533 in Type 1 Diabetes Pediatric and Young Adult Subjects

Completed
2
44
Europe
CFZ533, Iscalimab, Placebo
Novartis Pharmaceuticals
Type 1 Diabetes Mellitus
01/24
06/24
NCT03827798 / 2018-002757-30: Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

Active, not recruiting
2
248
Europe, US, RoW
CFZ533, Placebo to CFZ533, LYS006, Placebo to LYS006, MAS825, Placebo to MAS825, LOU064 25mg, LOU064 100mg, Placebo to LOU064, VAY736, Placebo to VAY736
Novartis Pharmaceuticals
Hidradenitis Suppurativa
12/24
11/26
abiprubart (KPL-404) / Kiniksa
2022-000169-42: Phase 2 study of the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KPL-404 in subjects with moderate to severe Rheumatoid Arthritis

Not yet recruiting
2
131
Europe, RoW
KPL-404, Solution for injection
Kiniksa Pharmaceuticals, Ltd., Kiniksa Pharmaceuticals, Ltd.
Rheumatoid arthritis (RA), Rheumatoid arthritis (RA), Diseases [C] - Musculoskeletal Diseases [C05]
 
 
NCT05198310: Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor

Completed
2
145
Europe, US, RoW
KPL-404, Placebo
Kiniksa Pharmaceuticals, Ltd.
Arthritis, Rheumatoid
02/24
05/24
NCT06531395: A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's Disease

Recruiting
2
200
US
Abiprubart, KPL-404, Placebo
Kiniksa Pharmaceuticals International, plc, Kiniksa Pharmaceuticals, GmbH
Sjögrens Disease
12/26
07/27
CD40.HIVRI.Env / ANRS
NCT04842682: Dose Escalation Trial of CD40.HIVRI.Env Vaccine Combined or Not With a DNA-HIV-PT123 HIV-1 Vaccine in Healthy Volunteers

Active, not recruiting
1
72
Europe
Solo 0.3 group, Solo 1 group, Solo 3 group, Combi 0.3 group, Combi 1 group, Combi 3 group
ANRS, Emerging Infectious Diseases
Healthy Adults
11/24
11/24
NCT06665646: Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in the HVTN706/MOSAICO Study and Remain Without HIV

Not yet recruiting
1
40
RoW
Hiltonol
National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
07/26
05/27

Download Options